Clinical trial
A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine
NCT02873286 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Single-blind, Placebo Controlled, Dose-ranging Phase II Trial in ≥ 55 Year Old Adults to Evaluate the Safety and Immunogenicity of the Recombinant MVA-BN-RSV Vaccine
- Lead sponsor
- Bavarian Nordic
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 30, 2016
- Completion date
- December 31, 2018
- Enrollment
- 420 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.